Summary
The pharmacokinetics and the pharmacodynamic action of dopamine were investigated in 5 healthy subjects. Dopamine was given in different doses (200, 400 and 800 µg/min) by constant intravenous infusion over 90 min. In order to control the influence of the procedure on the measured parameters the subjects also received a similar infusion of saline. Dopamine, noradrenaline and adrenaline levels in plasma were followed for up to 6 h after the infusion, and arterial pressure and heart rate were monitored. Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 µg/l at 200 µg/min, 73.8 µg/l at 400 µg/min and 207 µg/l at 800 µg/min. The corresponding total clearances were 5.8 l/ min, 5.51/min and 3.9 l/min suggesting non-linear kinetics. The kinetics could not be described by compartmental model. Noradrenaline and adrenaline levels were found to be elevated during infusion of dopamine. Noradrenaline had returned to its pretreatment level within 15 to 30 min after cessation of the infusion, whereas the adrenaline level did not return to the pretreatment value within the observation period. Heart rate was increased by the dose of 400 µg/min, and the systolic and mean arterial pressures were elevated, whereas distolic blood pressure remained unchanged. Elevated systolic blood pressure was better correlated with plasma dopamine than with noradrenaline concentration. This finding, in conjunction with the unchanged diastolic blood pressure, indicates that elevation of the systolic blood pressure is a direct rather than an indirect effect of dopamine. The increased heart rate was not correlated with the dopamine level.
Similar content being viewed by others
References
Abrahamsen AM, Storstein L, Westlie L, Storstein O (1974) Effects of dopamine on hemodynamics and renal function. Acta Med Scand 195: 365–373
Amsterdam EA, Bonansio J, Mansur R, Massumi R, Zelin R, Mason DT (1972) Effects of dopamine on hemodynamics and myocardial metabolism in patients with coronary artery disease. Clin Res 20: 202
Beregovich J, Bianchi C, Rubler S, Lomnitz E, Cagin N, Levitt B (1974) Dose-related hemodynamics and renal effects of dopamine in congestive heart failure. Am Heart J 87: 550–557
Engelman K, Portnoy B (1970) A sensitive double-isotope derivative assay for dopamine and epinephrine. Circ Res 26: 53–57
Francis GS, Sharma B, Hodges M (1982) Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 103: 995–1000
Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24: 1–27
Goodall McC, Alton H (1968) Metabolism of 3-hydroxytyramine (Dopamine) in human subjects. Biochem Pharmacol 17: 905–914
Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Vereinfachte Regeln zur Herleitung von analyzischen Lösungen für lineare Kompartimentmodelle. Arzneimittelforsch 27: 904–911
Holzer J, Karliner JS, O'Rourke RA, Pitt W, Ross J Jr (1973) Effectiveness of dopamine in patients with cardiogenic shock. Am J Cardiol 32: 79–84
Horwitz D, Fox SM, Goldberg LI (1962) Effects of dopamine in man. Circ Res 10: 237–243
Iversen LL (1974) Uptake mechanisms for neurotransmitter amines. Biochem Pharmacol 23: 1927–1935
Järnberg PO, Bengtsson L, Ekstrand J, Hamberger B (1981) Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. Acta Anaesth Scand 25: 328–331
Kho TL, Henquet JW, Punt R, Birkenhäger WH, Rahn KH (1980) Influence of dobutamine and dopamine on hemodynamics and plasma concentrations of noradrenaline and renin in patients with low cardiac output following acute myocardial infarction. Eur J Clin Pharmacol 18: 213–217
Loeb NS, Winslow EBJ, Rahimtoola SH, Rosen KM, Gunner RM (1971) Acute hemodynamic effects of dopamine in patients with shock. Circulation 44: 163–173
Mc Donald RH Jr, Goldberg LI, Mc Nay JL, Tuttle EP Jr (1964) Effects of dopamine in man: Augmentation of sodium ecretion, glomerular filtration rate and renal plasma flow. J Clin Invest 43: 1116–1124
Nash CW, Wolff SA, Ferguson BA (1968) Release of tritiated noradrenaline from perfused rat hearts by sympathomimetic amines. Can J Physiol Pharmacol 46: 35–42
Reid PR, Thompson WL (1975) The clinical use of dopamine in the treatment of shock. John Hopkins Med J 137: 276–281
Rosenblum R, Tai AR, Lawson D (1972) Dopamine in man: Cardiorenal hemodynamics in normotensive patients with heart disease. J Pharmacol Exp Ther 183: 256–263
Thompson WL (1977) Dopamine in the management of shock. Proc R Soc Med 70 [Suppl 2]: 25–35
Tuttle RR, Mills J (1975) Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36: 185–196
Zarolinski JF, Possley LH, Schwartz RA, Morris RN, Carone FA, Browne RK (1977) The pharmacology and subacute toxicology of dopamine. Proc R Soc Med 70 [Suppl 2]: 2–10
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gundert-Remy, U., Penzien, J., Hildebrandt, R. et al. Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. Eur J Clin Pharmacol 26, 163–169 (1984). https://doi.org/10.1007/BF00630281
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00630281